Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Budesonide  COVID-19 treatment studies for Budesonide  C19 studies: Budesonide  Budesonide   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Hospitalization 54% Improvement Relative Risk Hospitalization/ER 81% primary Recovery 15% Recovery time 7% post-hoc primary c19budesonide.com Clemency et al. NCT04377711 Budesonide RCT EARLY TREATMENT Favors budesonide Favors control
Clemency, 400 patient budesonide early treatment RCT: 54% lower hospitalization [p=0.26], 81% fewer combined hospitalization/ER visits [p=0.03], and 15% improved recovery [p=0.25] https://c19p.org/clemency
copied to clipboard
Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19
Clemency et al., JAMA Internal Medicine, doi:10.1001/jamainternmed.2021.6759, NCT04377711 (history)
22 Nov 2021    Source   PDF   Share   Tweet
RCT 400 outpatients in the USA, showing significantly lower ER visits/hospital admission with ciclesonide treatment. NCT04377711 (history).
Publication was delayed about a year after completion and the primary endpoint was changed about 4 months after the end of the trial on April 9, 2021 [clinicaltrials.gov, trialsitenews.com]. The original primary outcome was the more important ER visits/hospital admission, which shows a statistically significant improvement OR 0.18 [0.04-0.85].
risk of hospitalization, 54.1% lower, RR 0.46, p = 0.26, treatment 3 of 197 (1.5%), control 7 of 203 (3.4%), NNT 52, odds ratio converted to relative risk.
risk of hospitalization/ER, 81.2% lower, RR 0.19, p = 0.03, treatment 2 of 197 (1.0%), control 11 of 203 (5.4%), NNT 23, odds ratio converted to relative risk, primary outcome.
risk of no recovery, 15.1% lower, RR 0.85, p = 0.25, treatment 58 of 197 (29.4%), control 74 of 203 (36.5%), NNT 14, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, day 30.
recovery time, 7.4% lower, relative time 0.93, p = 0.55, treatment 197, control 203, inverted to make RR<1 favor treatment, Cox regression, post-hoc primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Clemency et al., 22 Nov 2021, Double Blind Randomized Controlled Trial, USA, peer-reviewed, 7 authors, study period 11 June, 2020 - 3 November, 2020, trial NCT04377711 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperBudesonideAll
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit